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Abstract
Platelet activating factor (PAF) has long been associated with acute edema and inflammatory responses. PAF acts by
binding to a specific G-protein coupled receptor (PAF-R, Ptafr). However, the role of chronic PAF-R activation on sustained
inflammatory responses has been largely ignored. We recently demonstrated that mice lacking the PAF-R (Ptafr-/- mice)
exhibit increased cutaneous tumorigenesis in response to a two-stage chemical carcinogenesis protocol. Ptafr-/- mice also
exhibited increased chronic inflammation in response to phorbol ester application. In this present study, we demonstrate
that topical application of the non-hydrolysable PAF mimetic (carbamoyl-PAF (CPAF)), exerts a potent, dose-dependent, and
short-lived edema response in WT mice, but not Ptafr -/- mice or mice deficient in c-Kit (c-KitW-sh/W-sh mice). Using an ear
inflammation model, co-administration of topical CPAF treatment resulted in a paradoxical decrease in both acute ear
thickness changes associated with a single PMA application, as well as the sustained inflammation associated with chronic
repetitive PMA applications. Moreover, mice treated topically with CPAF also exhibited a significant reduction in chemical
carcinogenesis. The ability of CPAF to suppress acute and chronic inflammatory changes in response to PMA application(s)
was PAF-R dependent, as CPAF had no effect on basal or PMA-induced inflammation in Ptafr-/- mice. Moreover, c-Kit
appears to be necessary for the anti-inflammatory effects of CPAF, as CPAF had no observable effect in c-KitW-sh/W-sh mice.
These data provide additional evidence that PAF-R activation exerts complex immunomodulatory effects in a model of
chronic inflammation that is relevant to neoplastic development.
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Introduction
Platelet activating factor (1-alkyl-2-acetyl glycerophosphocho-
line, PAF) is a bioactive lipid molecule produced by both
enzymatic and non-enzymatic mechanisms [1]. Non-enzymatic
production of PAF is dependent on free-radical mediated
modification of the sn-2 polyunsaturated fatty acid of glyceropho-
sphocholines to form PAF itself and other oxidized glyceropho-
sphocholines (ox-GPCs) that exhibit the ability to activate the PAF
receptor [1–5]. The biological activity of PAF is mediated by
binding to a single G-protein coupled receptor (PAF-R) that is
expressed on a wide variety of cells including keratinocytes [1,6,7].
Once produced, PAF elicits a variety of physiological and
pathological effects that play a role in acute inflammation, wound
healing, and angiogenesis. However, PAF is perhaps best known
for its pro-inflammatory effects that mediate the systemic reaction
to shock, allergic reactions, and anaphylaxis [1]. In this role, PAF’s
actions are thought to be mediated by its ability to stimulate
vasodilation and vascular permeability, platelet aggregation,
bronchoconstriction, and alterations in leukocyte function [1].
These effects on leukocytes include the ability of PAF to stimulate
mast cell activation and migration [8–10], mononuclear and
neutrophilic phagocytosis [11–13], and M2 polarization of
macrophages [14].
While it is clear that PAF acts to promote acute inflammatory
effects, particularly those associated with anaphylaxis and shock,
more recent evidence suggests that PAF may play a more complex
role in immune function. PAF production through enzymatic and
oxidative pathways appears to play a role in keratinocyte responses
to genotoxic agents, such as ultraviolet B, cigarette smoke or
chemotherapeutic agents [3,15–18]. Studies on the mechanisms of
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ultraviolet B (UVB)-induced systemic immunosuppression have
demonstrated a requirement for PAF-R activation [3,10,19,20].
This UVB-induced systemic immunosuppression is characterized
by an antigen-specific suppression of adaptive T-cell mediated
immune responses [21,22]. In addition, we have recently
demonstrated that Ptafr-/- mice exhibit an increase in cutaneous
chemical carcinogenesis that is associated with a corresponding
increase in phorbol ester (PMA)-induced cutaneous inflammation
[7]. This data suggests that PAF-R activation may be also be
important in regulating the innate immune system. However, the
down-stream cellular mediators of this immunomodulatory
activity are unknown.
The c-Kit gene codes for a receptor tyrosine kinase that binds
the ligand, stem cell factor (SCF), and is important in [23]. The c-
KitW-sh (sash) mutation is an inversion of a 3.1 Mbp segment that
disrupts the promoter region of the c-Kit gene [23]. Mice
homozygous for the c-KitW-sh mutation exhibit a profound loss
of mast cells, but also lack melanocytes and interstitial cells of Cajal
[23,24]. Thus, c-KitW-sh/W-sh mice represent a common tool to
assess mast cell function. Mast cells are tissue resident bone
marrow derived cells, which like PAF, are well known mediators of
allergic and anaphylactic reactions [25]. Mast cells are strategically
localized in the subepithelial and submucosal spaces prone to
environmental and infectious insults [25]. Moreover, the ability of
PAF to promote anaphylactic responses is dependent on mast cell
activation [8]. PAF is also a known activator and chemotactic
agent for mast cells [9]. In addition to their role in promoting the
wheel and flare reaction associated with type I hypersensitivity
reactions, mast cells have also been shown to suppress chronic
inflammation as well as adaptive immune responses [26–31]. Of
particular relevance, mast cells act to limit murine models of
contact hypersensitivity and chronic UVB-induced inflammation
[32]. In addition, the role of the PAF-R in UVB-induced
immunosuppression has been shown to result from PAF-R-
dependent migration of mast cells to the lymph node, wherein
they exert an interleukin (IL)-10-dependent immunosuppressive
effect [10].
While we recently provided evidence that PAF has anti-
inflammatory effects on chronic PMA-induced tumor promotion
[7], it is possible that the effects of germ-line loss of the PAF-R
could be due to compensatory embryonic or postnatal alterations
in skin development [7]. Thus, a demonstration that PAF-R
agonist treatment results in suppression of DMBA/PMA-induced
carcinogenesis and inflammation would provide further support to
the idea that the PAF-R has important anti-neoplastic and
immunomodulatory effects. Our current studies examining the
role of the PAF-R in PMA-induced inflammation adds to our
previous report and reveals a complex immunomodulatory role for
PAF-R signaling. Moreover, our findings using c-KitW-sh/W-sh mice
demonstrate a role for c-Kit and possibly mast cells in the
immunomodulatory effects of PAF.
Methods
Ethics statement
The protocols were approved by the Committee on the Ethics
of Animal Experiments of the Indiana University School of
Medicine (Institutional Animal Care and Use Committee
(IACUC) (Protocol Number: 3841 and 10639). Every attempt
was made to minimize animal suffering.
Reagents and chemicals
Phorbol 12-myristate 13-acetate (PMA) was purchased from
Promega, Madison, WI. 7,12-Dimethylbenz(a)anthracene (DM
BA) was obtained from Acros Organics, Fair Lawn, NJ. Carbamyl-
PAF was obtained from Sigma-Aldrich (St. Louis, MO).
Animals
Ptafr knockout (Ptafr-/-) in the C57BL/6 background were
originally obtained from Dr. Satoshi Ishii (Department of
Biochemistry and Molecular Biology, Faculty of Medicine, The
University of Tokyo), derived as previously described [33]. Age (8–
12 week)-matched Ptafr +/+ C57BL/6 (WT) were used as
controls (The Jackson Laboratories, Bar Harbor, ME). SKH-1
hairless, albino mice were obtained from Charles Rivers
(Wilmington, MA). Mice containing the W-sash (W-sh) inversion
mutation in the promoter region of the c-kit gene (KitW-sh) were
obtained from the Jackson Laboratories in the C57Bl/6
background (B6.Cg-KitW-sh/HNihrJaeBsmGlliJ). Mice were
housed under specific pathogen-free conditions at the Indiana
University School of Medicine.
Ear thickness measurements
The left ear of each mouse was treated with 20 ml of cPAF (0.1,
0.3, or 1 mM in acetone). The right ear was treated with 20 ml of
vehicle (acetone) alone. For PMA treatments, the left ear was
treated with 10 mg of PMA in 20 ml of acetone, and the right ear
was treated with vehicle (VEH) alone 3 times a week (arrows) for
16 days. For PMA and CPAF treatments, the mice were treated
with PMA first, then 20 ml of 0.3 mM CPAF (in acetone) was
added immediately after the PMA treatment. Ear thickness was
measured at the indicated time points following treatment using a
constant pressure analog thickness gauge (Peacock Model G,
0.4 N).
Epidermal thickness measurements
Mouse ears were treated for 18 days thrice weekly with vehicle,
CPAF (6 nmole), PMA, or PMA and CPAF were formalin fixed
and paraffin embedded (FFPE), and stained with hematoxylin &
eosin (H&E). Epidermal thickness was measured by measuring the
epidermal thickness 10 times in 5 consecutive 200 x fields, starting
at the distal tip of the ear and moving proximally to the next
adjacent field. Epidermal thickness was quantitated using an
eyepiece reticle calibrated with a stage micrometer. All slides were
blinded prior to measurement.
Tumorigenesis studies
For two stage chemical carcinogenesis studies, the dorsal skin of
SKH-1 hairless mice were treated with once with DMBA, followed
by repetitive treatments with PMA as previously described [7]. For
tumor counting, only durable tumors .1 mm in greatest diameter
were counted. After 25 weeks of PMA treatment, mice were
sacrificed and tumor size (size at greatest dimension) was measured
for each tumor. FFPE tumor sections from WT and Ptafr -/- mice
were stained with H&E and the tumor type (Papilloma and
microinvasive SCC (MISCC)) was assessed in blinded fashion by a
board-certified dermatopathologist, as previously described [34].
For MPO activity, tumor-free areas of treated skin were removed
and MPO activity levels were assessed as previously described
[35].
PMA-induced inflammation in dorsal epidermis
The back skin of female WT or Ptafr-/- mice was shaved under
anesthesia and was then treated with PMA or vehicle three times a
week for 18 days as described above. Immediately after each PMA
application, the mice were treated with vehicle or 100 ml of
0.3 mM CPAF (in acetone). On day 18, the mice were sacrificed
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and the treated dorsal epidermis was excised for skin thickness
measurements, as previously described [35].
Mast cell counting
Mast cells were stained with toluidine blue in deparaffinized
FFPE sections as described [36]. Four 200x images per biopsy
specimen were captured sequentially along the length of the
section using a Nikon Eclipse 80i. Nikon Elements Basic Research
Image Analysis software (v. 4.13) was used to count the mast cells
and measure the dermal area of interest. The total area and cell
counts were then averaged [(mast cells/mm2)x1025]. Given that
mast cell counts differ at different body sites in mice, mast cell
counts were performed in both the ears and the dorsal (back)
epidermis.
Statistical analysis
Statistical significance was assessed by Prism 5.0 software
(Graph Pad Software, San Diego CA) and significance was set as
p,0.05.
Results
CPAF is topically active and results in a dose-dependent
transient increase in ear thickness that is dependent on
mast cells
In a previous study [7] and in Fig 1A, we show that a single
topical application of increasing doses of the non-hydrolyzable
PAF-R agonist, CPAF, results in a dose-dependent increase in ear
thickness at two hours after application. In Fig 1B, a time course
study demonstrates that CPAF-induced ear thickness changes
occur rapidly, with significant increases in ear thickness noted by
1 hour after application and peak ear thickness was noted at 2 hrs.
Importantly, following a single application of CPAF the changes in
ear thickness were transient and declined to near baseline by
8 hours after application. The rapid and transient nature of the
response strongly suggests that changes in vascular permeability
leading to edema formation are largely responsible for the changes
in ear thickness. This is consistent with the well-known ability of
PAF to induce vasodilation and vascular permeability [37]. To
rule out PAF-R independent effects [38], mice with germline loss
of the Ptafr gene (Ptafr-/- mice) were also treated with CPAF. At
all doses studied, topical CPAF application failed to elicit an
inflammatory reaction in Ptafr-/- mice (Figs 1A&B), verifying the
specificity of the pharmacological effect.
Finally, the ability of CPAF to induce rapid edema reactions has
been linked to mast cell activation [8,9]. We therefore determined
whether the ability of CPAF to induce an early edema reaction at
2 hrs could be blocked in mice lacking mast cells (c-KitW-sh/W-sh
mice). In Fig 2 we verify that mast cells are indeed required for the
early increase in ear thickness mediated by CPAF application.
Topical CPAF protects against cutaneous chemical
carcinogenesis
The studies in Fig 1 demonstrate that CPAF exhibits specific
dose-dependent pharmacologic activity following topical applica-
tion. The use of a topical delivery approach also avoids potential
toxicities associated with systemic PAF-R agonist treatment [37].
In addition, the PAF-R is prone to the phenomenon of ligand-
induced down-regulation and desensitization [1,39]; this regula-
tory feature is characteristic of G-protein coupled receptors and
can lead to a paradoxical loss of receptor activation by subsequent
ligand binding [1,40]. Thus, given that carcinogenesis studies
would require long-term repetitive application of CPAF, we
utilized the 0.3 mM concentration of CPAF which induced an
intermediate, but significant increase in ear thickness measure-
ments (Fig 1A). For these studies, CPAF was applied immediately
after DMBA or PMA application for the duration of the study.
Consistent with our previous study that demonstrated that
Ptafr-/- mice exhibit increased DMBA/PMA-induced tumor
formation, in Fig 3A we show that topical treatment of CPAF
resulted in a significant reduction in DMBA/PMA-induced tumor
burden. CPAF treatment also demonstrated a modest, but
significant protective effect on tumor incidence (Fig 3B). More-
over, while Ptafr-/- mice exhibited a significant increase in the
frequency of larger tumors [7], mice treated with topical CPAF
exhibited a significant increase in smaller tumor sizes (Fig 3C). In
addition, we previously demonstrated that Ptafr-/- mice exhibit
an increase in SCC formation relative to WT mice [7]. However,
in this current study, no frank SCCs were observed and mice
treated topically failed to exhibit a significant change in the
proportion of grade 1–3 papillomas or microinvasive SCCs (Figure
S1 in File S1). Finally, tumor-free areas of skin treated with CPAF
exhibited a marked reduction in DMBA/PMA-induced inflam-
mation, as assessed using myeloperoxidase (MPO activity), a
marker of granulocytic cell infiltrates (Fig 3D) [41]. This is
consistent with our previous results in -/- mice, which exhibited an
augmentation of MPO activity following chronic, repetitive PMA
treatments [7].
Topical CPAF treatment suppresses inflammation
induced by repeated applications of the tumor promoter
PMA
In our previous report [7], we showed that a first PMA
application induced a significant increase in ear thickness in WT
mice 2 days after application. A second PMA application resulted
in a further increase in ear thickness that partially resolved.
Thereafter, subsequent PMA applications failed to elicit further
increases in ear thickness. In contrast, a significant and persistent
increase in ear thickness was observed during the 18 days of PMA
treatments (sustained chronic inflammatory phase). As in our
previous study, loss of the PAF-R resulted in a blunting of the peak
ear thickness observed after the second PMA application, but a
higher level of sustained chronic inflammation after continued
thrice weekly PMA applications (Figure S2 in File S1 and [7]). We
therefore examined whether topical CPAF administration would
have the opposite effect and suppress the sustained chronic
inflammation induced by PMA treatment. In Fig 4A we show that
the application of topical CPAF immediately after each applica-
tion of PMA results in a significant reduction in both the peak
inflammatory response noted on day 4, as well as a reduction of
the sustained inflammatory response that was noted throughout
the period of PMA application (18 days). Interestingly, at these
later time points, CPAF had no effect on ear thickness
measurements in WT mice not treated with PMA, suggesting
that topical CPAF is ineffective in inducing a significant sustained
inflammatory response at the dose tested (0.3 mM). Finally, we
next demonstrated that the effect of CPAF was entirely dependent
on the PAF-R, as CPAF and Veh applications showed nearly
identical ear thickness measurements at all time points following
PMA application to Ptafr-/- mice (Fig 4B). While CPAF
significantly blocked PMA-induced ear thickness in WT mice
(Fig 4A), this response was completely lost in Ptafr-/- mice treated
with PMA (Fig 4B). Finally, in Fig 4C, we show that the ability of
CPAF to suppress PMA-induced skin thickness changes was not
dependent on anatomic site. CPAF significantly suppressed PMA-
induced increases in dorsal back skin thickness after 18 days of
thrice weekly treatment.
Topical PAF Suppresses PMA-Induced Inflammation and Carcinogenesis
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We next determined the histopathologic changes in ear skin that
result from multiple PMA applications with or without CPAF
treatments. Multiple PMA applications to mouse skin are known
to induce epidermal hyperplasia and leukocyte infiltration [42,43].
In Fig 5A–I, we show that multiple PMA applications to WT
mouse ears results in a clear increase in ear thickness accompanied
by dermal expansion, leukocyte infiltration and epidermal
hyperplasia. Moreover, co-treatment of WT mice ears with CPAF
resulted in a reduction in PMA-induced leukocyte infiltrates while
Ptafr-/- mice exhibited a marked increase in ear thickness, dermal
expansion, inflammatory cell infiltrates, and epidermal hyperplasia
(Fig 5A–H). Relative to WT mice, Ptafr-/- mice exhibited a
marked increase in granulocytic infiltrates following chronic PMA
treatments (Fig 5 and Figure S3 in File S1). Moreover, CPAF
treatment suppressed the observed PMA-induced inflammatory
infiltrates in WT, but not Ptafr-/- mice. This data is in agreement
with our previous study demonstrating that Ptafr-/- mice exhibit a
marked increase in MPO activity following PMA treatment [7], as
well as our data in Fig 3D that shows that CPAF treatment
suppresses MPO activity in DMBA/PMA treated mice. Since
neutrophils are shown to play an important role in mouse skin
photocarcinogenesis [35], this reduction in granulocytic infiltrates
could play an important role in the observed anti-tumor effects of
topical CPAF treatment in chemical carcinogenesis (Fig 3A&B).
Given that the degree of chronic inflammation is commonly
associated with epidermal hyperplasia, it is somewhat surprising
that while CPAF treatment suppressed PMA-induced granulocytic
inflammation in WT mice, CPAF treatment did not alter PMA-
induced epidermal hyperplasia in either WT or Ptafr-/- mice
(Fig 5I).
PAF exerts complex effects on the initial inflammatory
response to PMA application
The pro-inflammatory tumor promoter PMA is known to
induce a rapid edema reaction in mouse ears [42,43]. This is
followed by a gradual rise in leukocyte infiltration as measured by
MPO and/or N-acetylglucosaminidase (NAF) activity that peaks
at around 24 hrs [42,43]. Given that PAF is a potent vasoactive
lipid mediator that promotes rapid edema reactions [37], we next
examined how CPAF would affect early inflammatory changes
following the first PMA application in WT and Ptafr-/- mice. As
seen in Fig 6A, PMA treatment induces a rapid increase in ear
Figure 1. Dose and time related acute ear inflammation changes in response to topical CPAF. 1A. Topical CPAF dose-dependently induces
rapid inflammatory responses as measured by ear thickness measurements. One ear of WT and Ptafr (-/-) were treated with one of three doses of CPAF
(20 ml of a 0.1, 0.3, and 1.0 mM solution for a total treatment dose of 2, 6, or 20 nmole CPAF per ear). The contralateral ear was treated with acetone
alone (VEH). Ear thickness was measured prior to treatment and 2 hours after treatment. After the pretreatment ear thickness values were subtracted,
the mean and SEM were plotted (n = 4 for 20 nmole and n=8 for 2 & 6 nmole CPAF & VEH treated mouse ears). 1B. Topical CPAF treatment induces a
rapid, but transient increase in inflammation as measured by ear thickness changes. One ear of wildtype (WT) and Ptafr (-/-) mice was treated with 20 ml
of CPAF (20 nmoles of a 0.1 mM solution in acetone) and 20 ml of acetone (VEH) was applied to the contralateral ear. Ear thickness was measured just
prior to reagent application and at 1, 2, 4, and 8 hours after application. Results represent the mean and SEM (n = 4 mice) after subtracting the
pretreatment ear thickness. CPAF induced a significant increase in ear thickness in WT mice relative to the WT+VEH treated ears. *, p,0.05; **, p,
0.01; ***; p,0.001; 2-tailed t-test.
doi:10.1371/journal.pone.0111608.g001
Figure 2. CPAF induces transient ear thickness changes are
blocked in c-KitW-sh/W-sh mast cell deficient mice. WT and c-KitW-
sh/W-sh mice were treated with vehicle (VEH) alone on one ear, and 20 ml
of 0.3 mM CPAF (6 nmole) on the contralateral ear. Ear thickness was
measured both prior to and 2 hrs after reagent application. After
subtraction of the ear thickness at time 0, the mean and SEM were
plotted (n = 5 for WT mice, n = 4 for KitW-sh/W-sh mice). *, p,0.05; 2-tailed
t-test.
doi:10.1371/journal.pone.0111608.g002
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thickness that was first observed two hours after application. Ear
thickness changes peaked at approximately 24 to 48 hrs. In
contrast, Ptafr-/- mice exhibited a reduction in the initial ear
thickness changes noted at 2 & 8 hrs, suggesting that PMA-
induced edema responses were PAF-dependent. It was therefore
surprising to find that WT mice treated with CPAF immediately
after PMA application also exhibited an approximately 50% loss
of PMA-induced early ear thickness changes observed at 2 hrs
(Fig 6B). This suggests a complex role for the PAF-R in regulating
initial vasoactive edema changes in response to PMA.
While the above data suggests a complex role for the PAF-R in
regulating initial PMA-induced inflammation, similar results were
seen at 24 and 48 hrs, which represent the period in which
inflammation is heavily dependent on inflammatory cell infiltrates.
As with the 2 & 8 hr time points, Ptafr-/- mice exhibited
reductions in PMA-induced ear thickness changes at 24 & 48 hrs.
However, topical CPAF was also significantly suppressed the
PMA-induced increases in ear thickness that occurred at 24 &
48 hrs (Fig 6B). That these effects are PAF-R dependent are seen
by the complete loss of activity of CPAF in Ptafr-/- mice (Fig 6B).
Thus, topical CPAF exerted complex, but PAF-R-dependent
effects on PMA-induced edema and early inflammatory changes in
mouse ears.
Topical CPAF has no effect on PMA-induced
inflammation in c-KitW-sh/W-sh mice
While mast cells are known mediators of PAF-induced edema
reactions, PMA is also known to induce mast cell degranulation
and mast cell deficient mice exhibit a marked decrease in both
PMA-induced edema reactions and leukocyte infiltration [43–45].
Thus, we sought to determine whether CPAF would have any
effect on PMA-induced inflammation in c-KitW-sh/W-sh mice. In
Fig 7A, we show that c-KitW-sh/W-sh mice exhibit an impaired
PMA-induced ear inflammation response at 2 and 8 hrs,
consistent with a role in regulating early edema reactions. As in
previous studies [43], this data suggests an important role for mast
cells in the acute inflammatory effects of PMA on mouse skin.
Given that loss of the PAF-R resulted in a similar loss in PMA-
induced acute inflammatory effects, we determined whether c-
KitW-sh/W-sh mice were susceptible to CPAF-induced effects on
inflammation. In Fig 7B, we show that the ability of topical CPAF
to suppress PMA-induced ear thickness was absent in KitW-sh/W-sh
Figure 3. Topical application of CPAF suppresses DMBA/PMA-induced tumorigenesis. 3A. Topical treatment with CPAF suppresses DMBA/
PMA-induced tumor multiplicity. SKH-1 mice were treated once with DMBA+/- CPAF, then with PMA or PMA+CPAF for 25 weeks. Durable tumors were
counted on a weekly basis. Tumor multiplicity (Avg tumor number per mouse was plotted at each week. Results represent the mean and SEM for
n = 19–20 mice/group. p,0.05 for weeks 9–12,14–25; p,0.01 for week 13; Mann-Whitney U test. 3B. Topical CPAF delayed tumor incidence in mice
treated with DMBA/PMA. The percent of mice remaining tumor free over the 25 week chemical tumorigenesis study were plotted using a survival
curve. The treatment with CPAF resulted in a significant change in the tumor incidence, with a median time until first tumor occurrence of 8 weeks
for DMBA/PMA treated and 9 weeks for DMBA/PMA+CPAF treated mice. *, p,0.05; Log-rank (Mantel-Cox) Test. 3C. Topical CPAF treatment results in a
smaller number of large tumors ($3 mm in greatest diameter) after 25 weeks of treatment. Tumor size distribution was plotted as the number of tumors
in each size distribution for each treatment group. Histopathologic exam showed no significant difference in the rates of papilloma and SCC
formation between the treatment groups (not shown). ***, p=0.0001 Fisher’s exact test. 3D. DMBA/PMA-induced MPO activity is suppressed by CPAF.
After the mice were euthanized following 25 weeks of DMBA/PMA +/- CPAF treatment, tumor free areas of skin were excised and MPO activity was
assessed in tissue lysates. After normalization to total protein, MPO activity was plotted as the mean and SEM (n = 5–9 mice per group). **, p,0.05;
***, p,0.001; 2-tailed t-test.
doi:10.1371/journal.pone.0111608.g003
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Figure 4. Effect of CPAF treatment on ear thickness changes over an 18 day course of thrice weekly PMA applications in WT and
Ptafr-/- mice. 4A. Topical CPAF treatment suppresses PMA-induced changes in ear thickness in WT mice. CPAF (6 nmoles) alone or PMA +/- CPAF were
applied to WT mouse ears thrice weekly for 18 days. Skin thickness measurements were taken at time 0 and just prior to each reagent application.
After subtraction of the time 0 ear thickness, ear thickness changes were plotted as the mean and SEM (n= 4–5 mice per group). PMA relative to
PMA+CPAF (a), PMA+CPAF relative to CPAF(b); *, p,0.05; **, p,0.01; ***, p,0.001; 2-tailed t-test. 4B. Topical CPAF treatment is ineffective in altering
PMA-induced ear thickness changes in Ptafr-/- mice. Ptafr-/- mice were treated and assessed as in 4A above. For the sake of comparison, the data for
the PMA + CPAF treatment in WT mice is included. (mean and SEM; n = 4–5 mice per group). WT mice treated with PMA + CPAF exhibit a significant
decrease in ear thickness measurements relative to Ptafr-/- mice treated with PMA + CPAF (*, p,0.05; **, p,0.01; ***, p,0.001; 2-tailed t-test). 4C.
Topical CPAF treatment suppresses PMA-induced skin thickness increases in dorsal epidermis following 18 days of treatment. The dorsal epidermis of SKH-
1 mice was treated thrice weekly with vehicle, CPAF, PMA, or PMA + CPAF. Doses of PMA and CPAF were the same as that used for the tumorigenesis
studies in Fig 3. ***, p,0.05 relative to PMA treated skin; 2-tailed t-test (n = 3 per group).
doi:10.1371/journal.pone.0111608.g004
Topical PAF Suppresses PMA-Induced Inflammation and Carcinogenesis
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mice at all time points up to 48 hrs. Moreover, in the model of
repetitive PMA applications (Fig 7C), KitW-sh/W-sh mice exhibit a
phenotype that mimics the phenotype seen in Ptafr-/- mice (see
Figure S2 in File S1). Again, topical CPAF had no effect on PMA-
induced chronic inflammation in c-KitW-sh/W-sh mice (Fig 7C).
Finally, to verify that the changes in Ptafr-/- mice were not
simply due to a loss of dermal mast cells, we next counted dermal
mast cells in the ear skin of Ptafr-/- mice following 18 days of
treatment with vehicle or PMA (Figure S4 in File S1). There was
no significant difference in dermal mast cells in Ptafr-/- mice
Figure 5. Inflammatory infiltrates and epidermal thickness in WT and Ptafr-/- mouse ears treated chronically with CPAF, PMA or
PMA + CPAF. 5A–H. Inflammatory infiltrates are increased in Ptafr-/- mice treated with PMA, while CPAF suppresses inflammatory cell infiltrates in PMA
treated WT mice. After treating WT and Ptafr-/- mouse ears for 18 days with VEH, CPAF, PMA, or PMA + CPAF as described in Fig 4, mice were
sacrificed and the ears excised for formalin fixation, paraffin embedding and hematoxylin & eosin (H&E) staining. Photomicrographs taken at 400x
magnification are shown. 5I. PMA-induced epidermal thickness is augmented in Ptafr-/- mice, while CPAF has no effect on PMA-induced epidermal
thickness in either WT or Ptafr-/- mice. Epidermal thickness was measured in WT and Ptafr-/- mice treated for 18 days with VEH, CPAF, PMA, and PMA +
CPAF as described in Fig 4A&B. Epidermal thickness in mm is expressed in the mean and SEM for 3–4 ears per experimental group. Significantly
different from WT VEH control (a), significantly different from the Ptafr-/- VEH control (b). *, p,0.05; **, p,0.01; ***, p,0.001; 2-tailed t-test.
doi:10.1371/journal.pone.0111608.g005
Figure 6. Following a single application of PMA, Ptafr-/- mice exhibit a reduction in PMA-induced ear thickness while CPAF
treatment also induces a paradoxical PAF-R dependent decrease in PMA-induced ear thickness. For all studies in Figs 6, WT and Ptafr-/-
mice were treated with VEH, PMA, CPAF (6 nmole) or PMA + CPAF as described in Fig 4A&B. Ear thickness measurements were made just prior to
reagent application as well as at the indicated time points up to 48 hrs. 6A. Ptafr-/- mice exhibit a reduction in early and delayed ear thickness increases
following a single PMA application. Ear thickness plots for WT and Ptafr-/- mice treated with and without PMA are shown. Statistically significant
changes are noted to WT mice treated with PMA relative to Ptafr-/- mice treated with PMA. Results represent the mean and SEM of ear thickness after
subtracting the ear thickness at time 0 (n = 4–12 mice per group). *, p,0.05; **, p,0.01; t-test. 6B. Coadministration of topical CPAF blocks PMA-
induced increases in ear thickness at all time points (2–48 hrs). PMA-induced ear thickness changes were assessed in WT or Ptafr-/- mice treated with
PMA or PMA + CPAF. After subtracting the ear thickness at time 0, the ability of CPAF to suppress PMA-induced ear thickness changes was calculated
as a percentage inhibition of PMA-induced ear thickness increases. CPAF treatment resulted in a significant inhibition of PMA-induced ear thickness
changes at all time points (p,0.01–0.05; % inhibition significantly different from no inhibition, Wilcoxon Signed Rank Test). CPAF treatment had no
significant effect on PMA-induced ear thickness changes in Ptafr-/- mice (One sample analysis, Wilcoxon Signed Rank Test). The percent inhibition of
PMA-induced ear thickness changes by CPAF in WT mice was also significantly different than that seen in Ptafr-/- mice (*, p,0.05; **, p,0.01; t-test).
doi:10.1371/journal.pone.0111608.g006
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relative to WT mice in ears. This is in agreement with a recent
study by another group [10]. However, PMA failed to induce a
significant increase in mast cell numbers as previously reported
[46]. This difference may be due to the fact that we used a shorter
time period of PMA-induced inflammation than this previous
report.
Discussion
In this current study, we show that topical CPAF is pharma-
cologically active as it elicits a modest dose-dependent transient
increase in ear thickness. Ear thickness changes peak at 2 hrs and
are largely normalized at 8 hrs, consistent with transient edema
formation. This is consistent with the well-known effects of PAF as
a pro-inflammatory mediator. This pharmacological activity is
further shown to be dependent on the PAF-R and is lost in c-KitW-
sh/W-sh mice, suggesting a dependence on c-Kit as well. A major
finding of our earlier study was that the sustained inflammation
that occurs in response to repetitive PMA applications was
increased in Ptafr-/- mice. While the pro-inflammatory effects of
PAF are well known, this data suggests a counter regulatory role
for the PAF-R in limiting the chronic or sustained inflammation
associated with repeated PMA exposures. Consistent with this
idea, our new studies demonstrate that co-administration of topical
Figure 7. KitW-sh/W-sh mice exhibit a reduction in PMA-induced acute inflammation but an augmented chronic or sustained
inflammatory response to multiple PMA applications. For all experiments in Fig 7A–C, ear thickness measurements were made just prior to
reagent application as well as at the indicated time points up to 18 days. Results represent the mean and SEM of ear thickness (n = 4–14 mice per
group). *, p,0.05; **, p,0.01; ***, p,0.01; 2-tailed t-test. 7A. Mast cell deficient mice have a blunted initial inflammatory response to a single application
of PMA. WT and c-KitW-sh/W-sh mice were treated with VEH or PMA as described in Fig 4A&B. After subtracting the ear thickness at time 0 prior to PMA
application, ear thickness changes were plotted (n = 12–14 mice/group). Ear thickness changes were significantly reduced in c-KitW-sh/W-sh mice
treated with PMA relative to WT + PMA mice at 2 and 8 hrs following PMA application. ***, p,0.001. 7B. Following a single application of PMA, topical
CPAF treatment has no effect on PMA-induced ear thickness changes in c-KitW-sh/W-sh mice. PMA-induced ear thickness changes were assessed in WT or
c-KitW-sh/W-sh mice treated with PMA or PMA + CPAF. After subtracting the ear thickness at time 0, the ability of CPAF to suppress PMA-induced ear
thickness changes was calculated as a percentage inhibition of PMA-induced ear thickness increases. CPAF treatment resulted in a significant
inhibition of PMA-induced ear thickness changes at all time points (see also fig 6B). CPAF treatment had no significant effect on PMA-induced ear
thickness changes in c-KitW-sh/W-sh mice (Wilcoxon Signed Rank Test). The percent inhibition of PMA-induced ear thickness changes by CPAF in WT
mice was also significantly different than that seen in c-KitW-sh/W-sh mice (**, p,0.01, ***, p,0.001; t-test). 7C. Topical CPAF is inactive in KitW-sh/W-sh mice
while these mice also exhibit a reduction in acute inflammatory ear thickness changes observed in the first 4 days, but exhibit a significant increase in
chronic sustained ear thickness changes. Significant differences were noted at the indicated time points in WT mice treated with PMA relative to KitW-
sh/W-sh mice treated with PMA (a) as well as in WT mice treated with PMA/CPAF relative to KitW-sh/W-sh mice treated with PMA/CPAF (b).
doi:10.1371/journal.pone.0111608.g007
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CPAF along with PMA results in a suppression of the sustained
inflammatory response elicited by repetitive tumor promoter
application. Since chronic inflammation is thought to promote
carcinogenesis [35,47–49], we previously suggested that the
increased susceptibility to chemical carcinogenesis observed in
Ptafr-/- mice may be due to anti-inflammatory effects. This is
supported by our observations that topical CPAF suppresses
DMBA/PMA-induced carcinogenesis, and that this chemopre-
ventive activity correlates with a reduction in MPO activity.
In contrast to the effects of PAF-R activation on the sustained
inflammatory response to multiple PMA applications, PAF-R
signaling appears to exert complex pro-inflammatory and anti-
inflammatory effects during the initial PMA-induced edema and
inflammatory response observed in the first 48 hrs after a single
PMA application. Ptafr-/- mice exhibited a reduction in ear
thickness changes during the first 48 hrs following an initial PMA
application. This would be consistent with PAF-R activation
serving as a downstream mediator of PMA-induced acute
inflammatory responses. This is indeed consistent with the known
pro-inflammatory effects of PAF in regulating both edema and
leukocyte recruitment [42,43]. However, in our studies, topical
CPAF is shown to consistently induce a paradoxical suppression of
PMA-induced ear thickness at all time points following either a
single PMA application and at later time points following multiple
PMA treatments. The possibility that effects of exogenous CPAF
are not PAF-R dependent is highly unlikely, as CPAF had no
significant effect on PMA-induced inflammation at any time point
in Ptafr-/- mice.
It is unclear how CPAF application (PAF-R activation) and loss
of PAF signaling both result in reductions in PMA-induced edema
&/or leukocyte infiltration at early time points following a single
PMA application. This could indicate that exogenous CPAF exerts
a supraphysiologic response at the receptor level that suppresses
PMA-induced inflammatory signaling. It is known that some G-
protein coupled receptors, particularly those coupled to Gi-alpha
subunit signaling, can also activate Gbeta/gamma subunit
signaling when receptors are activated at a higher molar level
[50,51]. Alternatively, it is possible that CPAF exerts effects on
inflammation through a complex interplay between multiple cell
types with counter-regulatory functions.
A second major finding of our study is that c-Kit is likely critical
for our observed effects of CPAF on PMA-induced inflammation.
Topical CPAF failed to elicit a response in c-KitW-sh/W-sh mice at
all time points following PMA application(s). Like PAF, mast cells
have long been known to be pro-inflammatory mediators of type I
hypersensitivity reactions [52]. More recent data indicates that
mast cells exert complex effects on both innate and adaptive
immune responses [26–28]. The resistance of mast cell deficient
mice to the initial PMA-induced edema and inflammatory
response is consistent with previous studies demonstrating that
mast cell deficient mice exhibit a marked decrease in both PMA-
induced edema reactions and leukocyte infiltration [43–45].
Moreover, our data suggests that mast cells may be necessary for
the ability of CPAF to suppress the sustained inflammation
observed following multiple PMA applications. It might be noted
that a similar observation was noted in mice exposed to contact
allergen or chronic low dose ultraviolet B [32]. In this study, mast
cells limited the leukocyte infiltration, necrosis and epidermal
hyperplasia that were associated with these insults [32]. Since mast
cells can produce both pro-inflammatory and anti-inflammatory
mediators [29,31], it is possible that initially pro-inflammatory
mast cells alter their secretory phenotype under conditions of
repetitive chronic inflammatory stimuli resulting in a switch to
anti-inflammatory mediator release. This idea is supported by our
data that shows that c-KitW-sh/W-sh mice exhibit a reduction in the
initial PMA-induced inflammation, but exhibit enhanced sus-
tained chronic inflammation with chronic repetitive PMA
applications. The weak edema response noted by topical CPAF
administration is consistent with data indicating that PAF fails to
elicit histamine secretion from dermal mast cells from humans
[8,53], although PAF is a potent activator of histamine release
from mast cells derived from peripheral blood or lung tissue [8]. In
contrast, the ability of mast cells to promote immune suppression
following UVB irradiation depends on a PAF-dependent mast cell
migration to lymph nodes [10]. Finally, it should be noted that
melanocytes are absent in c-KitW-sh/W-sh mice. Moreover, c-KitW-
sh/W-sh mice also exhibit increased numbers of immature granu-
locytic myeloid derived suppressor cells (MDSCs) within the spleen
[23]. Thus, it is possible that some or all of the effects that we
observed in c-KitW-sh/W-sh mice are independent of mast cells or
require mast cell interaction with melanocytes or MDSCs.
While our findings demonstrate that c-KitW- sh/W-sh mice exhibit
enhanced inflammation following repeated PMA applications, a
recent study demonstrated that KitW/KitW-v mice exhibited a
decrease in inflammatory cell accumulation over a 7 week period
following DMBA treatment and repeated PMA applications [54].
It is possible that this discrepancy could be accounted for by the
absence of DMBA treatment in our studies. More likely, this
report is consistent with the known reduction in differentiated
bone marrow derived cells in KitW/KitW-v mice that is not
observed in c-KitW-sh/W-sh mice [24]. In support of this idea, KitW/
KitW-v mice also exhibited a reduction in total CD45+, CD8+, F4/
80+, and Gr-1+ cells prior to treatment [54].
While topical CPAF suppressed not only PMA-induced
inflammation, it also suppressed NMSC formation following
chemical carcinogenesis. Moreover, Ptafr-/- mice exhibit en-
hanced DMBA/PMA-induced tumorigenesis [7]. Given that c-Kit
appears to be critical to the effects of PAF on PMA-induced
inflammation, it would be of interest to perform future studies to
determine whether c-KitW-sh/W-sh mice exhibit increased tumori-
genesis in response to chemical carcinogens or UVB treatments. It
has been proposed that mast cells should promote skin cancer
formation through multiple mechanisms, particularly their ability
to suppress anti-tumor adaptive immune responses [29,30]. In
studies in which mast cells have been directly assessed in tumor
models, mast cells are associated with both pro-tumor and anti-
tumor activity in lymphoma and models of adenocarcinoma [55–
60]. Given the above discussion, it should be noted that a recent
study demonstrated that KitW/KitW-v mice exhibit a pronounced
increase in DMBA/PMA induced tumor formation [54]. Since
these mice exhibit changes in other bone marrow derived cell
types, it is important to note that this tumor phenotype was
reversed by mast cell reconstitution of the treated skin [54].
It has been proposed that PAF should promote skin cancer
formation secondary to its ability to induce a systemic T-cell
immunosuppression [61]. Similarly, our studies have shown that
PAF-induced immunosuppression promotes the growth of synge-
neic tumors in mice [19]. Thus, the ability of topical CPAF to
suppress chemical carcinogenesis in mice would run counter to
previous thoughts regarding the role of PAF in tumorigenesis. It is
possible that both mast cells and PAF-R activation act to promote
tumor formation via loss of immune surveillance mechanisms, but
this is countered by their ability to suppress the promoting aspects
of cutaneous inflammation. Thus, it may be that a tissue or context
dependent balance between adaptive and innate immune system
immunoregulation may determine the ultimate role of PAF in
tumorigenesis. Alternatively, relatively high UVB doses are
required to induce systemic immunosuppression [62]. This implies
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that relatively high systemic concentrations of PAF are necessary
to induce systemic immunosuppression. Thus, it is possible that
our relatively low doses of topical CPAF administration may
readily elicit a suppression of local inflammation, but have
minimal effects on systemic immunosuppression. The use of
higher topical doses or systemic administration of CPAF in our
current model may prove informative in future studies to address
this idea. Finally, chronic repetitive PMA and/or CPAF applica-
tions could act to promote a change in specific mast cell mediator
release, to promote an altered balance of phenotypically distinct
mast cells (MMC or CTMC), or alter the microenvironmental
cues that drive mast cell function. In any case, future studies are
necessary to better address the relative role of PAF in altering both
adaptive and innate immune responses in cutaneous carcinogen-
esis. Further work is also necessary to determine whether PAF-R
signaling acts to suppress tumor formation in the more clinically
relevant photocarcinogenesis model.
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